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Abbreviations 
BiVAD – Bilateral Ventricular Assist Device 
ECMO – Extracorporeal Membranous Oxygenation 
IABP – Intra-Aortic Balloon Pump 
LVAD- Left Ventricular Assist Device 
NHSBT – National Health Service Blood and Transplant 
OCS– Organ Care System (OCS™ Heart) by Transmedics Inc., Andover, MA, USA 
RVAD- Right Ventricular Assist Device 
VAD- Ventricular Assist Device 
 
Terminology 
Cold Ischemic Time – Duration of cold storage packed with ice after cold cardioplegia  
Warm Ischaemic Time – Time from application of cross clamp on donor aorta until heart is 
placed on ice plus implant time  
Implant time –time between removal from cold storage or OCS until the heart is re-perfused in 
the recipient 
Extracorporeal Time: Time spent on transferring the heart onto the OCS machine + Time the 
heart is perfused on the OCS machine + time from when heart is removed from the machine to 
the moment when the aortic cross clamp is removed following implantation into the recipient 
Inotrope Score -  dopamine(X1) + dobutamine(X1) amrinone (X1) + milrinone (X15) 
+adrenaline(X100) + noradrenaline(X100) with each drug dosed in μg/kg/min. 
Donor/recipient mismatch measurements were calculated as follows:   
[(Measure (recipient) − Measure(donor)/Measure(recipient)] X 100 
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Abstract 
Background: Heart transplantation (HTx) remains the most effective long-term treatment for 
advanced heart failure. Primary graft dysfunction (PGD) continues to be a potentially life-
threatening early complication. In 2014, a consensus statement released by ISHLT established 
diagnostic criteria for PGD. We studied the incidence of PGD across the UK. 
 
Methods: We analysed the medical records of all adult patients who underwent heart 
transplantation between October 2012-October 2015 in the 6 UK heart transplant centers 
Preoperative donor and recipient characteristics, intraoperative details and posttransplant 
complications were compared between the PGD and non PGD groups using the ISHLT 
definition. Multivariable analysis was performed using logistic regression.  
 
Results: The incidence of ISHLT PGD was 36%. Thirty-day all-cause mortality in those with 
and without PGD was 31(19%) vs 13(4.5%) (p=0.0001). Donor, recipient and operative factors 
associated with PGD were:  recipient diabetes mellitus (p=0.031), recipient preoperative 
BIVAD(p<0.001) and preoperative ECMO (p=0.023), female donor to male recipient gender 
mismatch(p=0.007) older donor age (p=0.010) and intracerebral haemorrhage/thrombosis in 
donor (p=0.023). Intra-operatively, implant time (p=0.017) and bypass time(p<0.001) were 
significantly longer in the PGD cohort. Perioperatively, patients with PGD received more blood 
products (p<0.001). Risk factors identified by multivariable logistic regression were donor age 
(p=0.014), implant time (p=0.038), female: male mismatch (p=0.033), recipient diabetes 
(p=0.051) and preoperative VAD/ECMO support (p=0.012), 
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Conclusion: This is the first national study to examine the incidence and significance of PGD 
after heart transplantation using the ISHLT definition. PGD remains a frequent early 
complication of heart transplantation and is associated with increased mortality. 
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Introduction 
Heart transplantation remains the most successful long-term treatment for advanced chronic 
heart failure. Survival after cardiac transplantation has improved but primary allograft 
dysfunction (PGD) remains a significant problem and the predominant cause of early mortality 
during the first month(1). In a previous UK study, the incidence of PGD was 32% using a study-
specific definition comprising of severely impaired systolic function affecting 1 or both 
ventricles accompanied by hypotension, low cardiac output, and high filling pressures occurring 
in the first 72 hours (in the absence of hyper acute rejection and technical surgical factors, such 
as cardiac tamponade)(2).  
However, comparative studies of the incidence and outcome of PGD have been hampered by the 
lack of an agreed definition until, in 2014, an international consensus statement was developed 
under the auspices of ISHLT.  
The consensus classified graft dysfunction as primary graft dysfunction (PGD) or secondary 
graft dysfunction which had a discernible cause such as hyper-acute rejection, pulmonary 
hypertension, or surgical complications. PGD must be diagnosed within 24 hours of completion 
of surgery. PGD is divided into PGD-left ventricle and PGD-right ventricle. PGD-left ventricle is 
categorized into mild, moderate, or severe grades depending on the level of cardiac function and 
the extent of inotrope and mechanical support required. Risk factors for PGD include donor, 
recipient, and surgical procedural factors(3).  
In this study, we aimed to ascertain the incidence of PGD using the ISHLT criteria and examine 
preoperative donor and recipient characteristics as well as procedural risk factors for PGD in a 
study of an unselected national population of adult heart transplants. 
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Methods 
Inclusion Criteria  
All first time orthotopic heart transplants in adults from donors after brainstem death (DBD). 
From October 2012-October 2015, 450 adult heart transplants which met our inclusion criteria 
were performed in the United Kingdom. Data were collected prospectively at the time of the 
heart transplant and incorporated into the UK Transplant database hosted by NHSBT. Data were 
retrospectively validated from case records for each of these patients and additional information 
necessary for the study was extracted from the clinical records by SS. Patients with combined 
organ transplants were excluded from this study. Donor procurement was performed by the 
National Organ Retrieval Service(NORS) with all but 1 center using 1 litre of cold St Thomas’s 
solution (supplied by Martindale Pharmaceuticals, Romford, Essex, UK) followed by cold stage 
packed with surrounding ice during transportation. One center utilized the OCS (TransMedics 
Inc) and used Custodiol solution cardioplegia (supplied by Pharmapal Ltd, Elstree, 
Borehamwood, UK) at the beginning and end of the OCS run. A Pulmonary Artery Catheter was 
inserted after the transplantation. If this was not possible, primary graft dysfunction was 
diagnosed using echocardiographic parameters as per Kobashigawa et al(3). Induction and 
maintenance immunosuppression was as per local hospital protocols.  
Primary Graft Dysfunction was defined using the 2014 ISHLT Consensus(3). 
The use of postoperative mechanical support was determined by individual surgeons  
 
Statistical Analysis 
Continuous variables were described by mean and standard deviation or by median and 
interquartile range as appropriate. Categorical variables were expressed as number and 
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proportion. Baseline characteristics were compared between PGD and non-PGD groups using 
Student’s t-test and Mann Whitney U test as appropriate and chi-square test or Fisher’s exact test 
for categorical variables. Variables with significance of p<0.1 in the unadjusted analysis were 
initially introduced as candidate variables in a multivariable logistic regression model for the 
probability of PGD and removed by stepwise backward elimination. Variables were retained in 
the model if they reduced the model deviance significantly (p<0.05). This was done using a 
complete case dataset to ensure appropriate comparison of nested models (however missing data 
were minimal due to interrogation of data at source). A further subgroup analysis was performed 
on just those with PGD using the same methodology to compare variables that predict the 
different severities of PGD as defined. Analysis was conducted in Minitab 17 Statistical 
Software (2010). Minitab, Inc. 
 
Results 
450 adults received heart transplants between 1 October 2012- 1 October 2015. The mean age 
was 46.3±13.5 years. 348 (77.3%) of the recipients were males. During this period there were 10 
Donation after Circulatory Death (DCD) transplants and these were excluded from the study. 
There were also 3 patients who were re-transplanted. Their second transplants were excluded 
from this study. 98.2% of patients had PA catheters inserted postoperatively. Preoperative, 
operative and postoperative details of the PGD and non-PGD cohorts are shown in Table 1. The 
overall incidence of Primary Graft Dysfunction was 36.2% (163 patients). There were 7 (16%) 
cases of Secondary Graft Dysfunction. These were graft failure secondary to bleeding, 
hyperacute rejection and elevated pulmonary pressures as defined by Kobashigawa et al(3).The 
phenotype and severity of PGD is shown in Figure 1. 
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We identified donor, recipient and operative risk factors for PGD. Preoperative factors that were 
significantly associated with PGD in the unadjusted analysis were recipient diabetes mellitus, 
and female donor to male recipient gender mismatch (Table 1). There was no significant 
difference between the donor-recipient height and weight mismatch but the estimated LV mass 
showed more downsizing of donor to recipient in the PGD cohort. Intra-operatively, implant 
time and bypass time were significantly longer in the PGD cohort (Table 2)). Patients with PGD 
had increased transfusion of blood products (Table 3). 30-day mortality for patients with primary 
graft dysfunction was 31(19%) vs 13(4.5%) (p<0.001). The 6-month mortality for patients with 
PGD was 52 (31.9%) vs 18 (6.3%) (p<0.001). Comparing the PGD groups, there was a 
significantly higher 30-day mortality in the severe PGD-LV group vs moderate PGD-LV group 
27(30%) vs 4(5%) respectively, p<0.001). 
The total extracorporeal time for the OCS subset was significantly longer than after cold storage 
(309.4±88.4 minutes vs 100.3±45.8 minutes; p<0.001. However, the incidence of PGD was 
similar to the non-OCS cases (30.3% vs 37.2%, respectively) (p=0.279). In a subgroup analysis 
of the OCS cases, extracorporeal time was significantly longer in the PGD group (344.9±95 
minutes vs 294.8±81 minutes; p=0.048) 
The following variables were considered for a multivariable analysis of the probability of PGD 
in which 21 (5%) patients were excluded due to missing data.  
Continuous Variables: Recipient age, donor age, explant time, implant time  
Categorical Variables: Recipient diabetes, recipient preoperative inotropes, recipient 
preoperative VAD/ECMO support, female donor: male recipient mismatch, donor smoking 
history, OCS usage, recipient aetiology, donor cause of death and recipient preoperative IABP 
usage.  
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Bypass time and total blood were excluded from this analysis because these results may have 
arisen from Primary Graft Dysfunction rather than being causative of it. OCS use was not 
included because it occurred in a small surgeon-selected subset. The final model is shown in 
Table 4. 
In donors, the likelihood of PGD increased by 20% for each decade increment in donor age. A 
female donor: male recipient combination was 1.7 times more likely to develop PGD.  
Recipients requiring preoperative mechanical circulatory support also conferred almost a 2-fold 
increase in likelihood of PGD. Diabetic recipients were more than twice likelier to develop PGD. 
There was also 1% increase for each minute increment during implantation of the heart.  
As an illustrative example, the absolute risk of developing PGD in an average donor (40-year 
old) to an average recipient (nondiabetic, no preoperative MCS, implant time = 54 minutes, 
without female donor to male recipient gender mismatch) was 28.7%. This absolute risk 
increased to 45.1% if there was recipient diabetes or 41.9% if there was preoperative MCS. A 
female donor to male recipient increased the absolute risk to 41.2%. 
The absolute PGD risk of advancing donor age in an average recipient is computed in the Figure 
2a. Figure 2b shows the effect of advancing implant time (mins) in a 40-year old donor to an 
average recipient, who wasn’t on any MCS support. 
A further subgroup logistic regression analysis was performed to identify risk factors for severe 
PGD vs mild/moderate PGD on the 163 patients who experienced some degree of PGD. The 
variables included for analysis were 
Continuous Variables: Recipient age, donor age, explant time, implant time  
Categorical Variables: Recipient diabetes, recipient preoperative inotropes, recipient 
preoperative VAD/ECMO support, female donor: male recipient mismatch, donor smoking 
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history, OCS usage, recipient aetiology, recipient re-sternotomy donor cause of death and 
recipient preoperative IABP usage  
This subgroup analysis revealed implant time, female donor: male recipient gender mismatch 
and recipient re-sternotomy to be independent risk factors for severe PGD as opposed to mild or 
moderate PGD as seen in Table 5. 
 
Discussion 
This study is the first national study of PGD in an unselected population of adult heart 
transplants using the ISHLT consensus definition. The main findings were, first, a high overall 
incidence of PGD and, second, a significant increase in perioperative mortality in the PGD 
group. Third, the risk factor analysis identifies not only donor and recipient factors but 
potentially modifiable procedural risk factors such as surgical implant time and use of blood 
products. Finally, the use of the OCS allowed an extension of the extracorporeal time for the 
donor heart with a similar incidence of PGD. Nevertheless, increasing extracorporeal time in the 
OCS group was associated with an increase in PGD indicating that any protection afforded by 
OCS was relative, not absolute. 
 
Incidence of PGD  
There was a relatively high incidence of PGD (36.2%) in this cohort. This finding is similar to 
that reported by Dronavalli et al which reported an incidence of about 32%(2). The changing 
patient demographics with increasing use of pretransplant mechanical circulatory support and 
increased utilization of marginal donors could be a contributory factors as donor age and 
preoperative MCS usage were independent risk factors for PGD(4). Dronavalli et al also 
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mentioned the lack of echocardiographic criteria which reduced the sensitivity of diagnosing 
PGD in the previous study. There were more severe PGD-LV patients (18%) and moderate 
PGD-LV (16%) than mild PGD-LV (1%) and PGD-RV (1%). These findings were similar 
findings noted in a single center series by Sabatino et al(5). Majority of their patients were 
classified as severe PGD (65%) followed by moderate (12%) and mild (0%; p < 0.01). The low 
rates of mild PGD-LV could be as a result of earlier intervention by physicians and surgeons by 
increasing the inotropic treatment in response to a low cardiac output state to the point where the 
inotrope score will meet the ISHLT definition of moderate PGD_LV. The clinical significance of 
the mild PGD-LV group is uncertain as there was no 30-day mortality in this group. 
 
PGD-related Mortality 
The 30-day mortality in our cohort was lower than the previous study (19% vs 37%) and in other 
studies(6-8).The lack of a standardized definition previously also potentially resulted in more 
conservative definitions of PGD which was the need for instituting MCS. This could also explain 
the improved mortality figures due to the inclusion of inotrope dependence as part of the 
definition. The improved 30-day survival could also be a result of improvements in recognition 
and treatment of PGD. Short term PGD related mortality rates in our cohort was also similar to 
that described by Squiers et al from a high volume center in the United States(9). They had a 30-
day mortality rate of 25% in the moderate/ severe PGD group. Sabatino et al also reported 
similar mortality rates in their cohort (37% in-hospital mortality)(5). However, the mortality rate 
at 6-months remains high in the PGD cohort (31.9% vs 6.3%). There is a paucity of data 
regarding longer term outcomes following PGD. Kim et al retrospectively reviewed a single 
center cohort of patients and noted that moderate and severe PGD-LV patients had worse long-
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term outcomes(10). Given the large proportion of moderate and severe PGD-LV patients in our 
cohort, further studies may be needed to evaluate longer term outcomes of PGD survivors vs 
non-PGD patients.  
 
Risk Factors 
The increased incidence of PGD reported is multifactorial. It highlights several vascular risk 
factors that may shed light on the aetiology of PGD. Increasing donor age and recipient diabetes 
were both independent risk factors in our cohort and have identified in previous studies prior to 
the ISHLT definition(8).  
Donor age was a significant risk factor for both PGD and severe PGD in the subgroup analysis. 
This finding was also noted by Russo et al during interrogation of the UNOS database(11). They 
concluded that the effect of ischemic time on survival after heart transplantation is dependent on 
donor age, with greater tolerance for prolonged ischemic times among grafts from younger 
donors.  
Ischemic time was subdivided into warm and cold ischemic time in our cohort(12). Warm 
ischemic time was defined as the explant time + the implant time. The implant time was found to 
be a strong predictor of primary graft dysfunction. Marasco et al(13) retrospectively reviewed 
206 patients over a period of around 10 years (June 2001-November 2010). Their definition of 
warm ischemic time included the implant time. They found that poorer survival with a warm 
ischemia time(WIT) of >80 minutes having a compared to WIT group of <60 minutes. Donor 
age was once again an independent predictor of outcome in this cohort.  
The role of recipient diabetes as a predictor of primary graft dysfunction was evident in our study 
as it was in the RADIAL study. The UK prospective Diabetes Study trial established a link 
14 
 
between microvascular complications and glycemic control(14). In recipients with diabetes, there 
may be a combination of direct glucose-mediated endothelial damage, oxidative stress from 
superoxide overproduction and production of advanced glycation end-products, which may result 
in changes in endothelial permeability, excessive vascular protein deposition and altered blood 
flow(15). A recent metanalysis, diabetes mellitus was an independent predictor of 1-year 
mortality postheart transplant(16). They attributed this to the summative increased hazard for 
comorbidities of diabetes at time of transplant which was also noted by Russo et al(17). In a 
subgroup analysis, diabetic recipients with well controlled diabetes had similar survivals to 
nondiabetic patients. Interrogation of the UNOS database by Taghavi et al(18) revealed that of 
20,348 patients undergoing orthotopic heart transplantation, 496 (2.4%) received hearts from 
diabetic donors. The diabetic donors were likelier to be females and older. The recipients of 
diabetic hearts were also older. However, on multivariable analysis of subgroups, neither insulin-
dependent diabetes (1.173; 95% CI, 0.884-1.444; P = .268) nor duration of diabetes for more 
than 5 years (HR, 1.239; 95% CI, 0.914-1.016; P = .167) were risk factors once the groups had 
been matched. A similar finding was noted by Smits et al (2012) in a European cohort(19).  
The odds ratio for severe PGD was double that of mild/moderate PGD in female donor – Male 
recipient gender mismatched patients in our study. It has also been identified as a risk in several 
previous studies. Jalowiec et al conducted a study on early outcomes after heart transplantation 
in gender mismatched patients(20). 74/347 patients received a heart from an opposite gender. 
They concluded that gender-mismatched heart transplant recipients had more complications due 
to rejection and higher resource utilization due to more re-hospitalization during the first 
postoperative year as compared to gender-matched recipients. Stehlik et al published similar 
findings with female donor: male recipients having a higher risk of posttransplant death(21). 
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Some have postulated the relative differences between the size (body surface area) or weight 
mismatch between female donor and male recipient, citing a smaller female donor heart being 
unable to sustain the demands of a larger male patient although there was no significant size 
mismatch (>20%) noted in our cohort(22, 23).  
Recipient re-sternotomy was identified as a risk factor for developing severe PGD in our 
subgroup analysis. Patients with previous sternotomies develop adhesions which complicate the 
surgical dissection thereby prolonging the explantation period and bypass time. They are also at 
an increased risk of infections(24).This may further exaggerate the inflammatory response 
explaining the need for increased support postoperatively. Analysis of the UNOS database 
revealed an increased risk of all cause mortality in patients with re-sternotomies.(24) 
 
OCS  
It is widely believed that an important factor in the pathogenesis of PGD is acute ischemia-
reperfusion injury. The donor heart is exposed to variable blood pressures, hypothermic storage, 
warm ischemia and finally reperfusion. The role of the OCS in reducing the impact of this has 
not been studied. A multivariable analysis has not been done here owing to the relatively small 
number of OCS transplants during the study period (n=66). However, in the unadjusted analysis, 
length of time on the OCS machine was a strong predictor of PGD. One hypothesis for this 
phenomenon is the lack of metabolic and excretory functions within the OCS circuit to sustain 
the metabolically active heart within the machine. The mean extracorporeal time of hearts on the 
OCS was significantly longer than cold storage with similar PGD rates. Garcia-Saez et al 
reported improved short-term outcomes from the use of the OCS in extended criteria donors(25). 
The OCS may have a role in improving logistical limitations of organ procurement. The ex-vivo 
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perfusion of the heart allows evaluation of extended criteria allografts prior to implantation. It 
also reduces functional ischemia by means of continuous oxygenation and perfusion which may 
be importance in higher risk recipients who are on MCS. Nevertheless, a randomized study of a 
larger cohort of donors is needed to establish any benefit of the OCS in reducing PGD.  
 
Size mismatch 
The height and weight profiles of donors and recipients in our cohort were not significantly 
different in both groups. This could be due to careful donor selection and matching process to 
ensure accurate sizing of the cardiac allograft for the recipient. Height mismatch and weight 
mismatch were negligible in our cohort. However, a composite of the 2 measurements to 
calculate the estimated LV mass showed a higher proportion of downsizing in the PGD cohort.  
We used the following equation which has been published and validated in the literature(26). 
Predicted left ventricular mass(g) = α X Height0.54 (m) X Weight0.61 (kg), 
where α = 6.82 for women and 8.25 for men 
However, this was not a significant finding on multivariable analysis. This could be due to the 
co-efficient weightage which may reflect the potential downsizing in a female donor to male 
recipient gender mismatch using this equation. The equation is also limited as there is no 
correlation with other confounders of LV mass such as ethnicity, history of cardiovascular 
disease and valvular heart disease. Size mismatching has been noted in other studies(5, 9, 27, 
28). Transplanted hearts are denervated and thus rely on increased stroke volume to augment 
workload(29). Consistent increments of stroke volume results in increasing filling pressure. 
Smaller hearts are also prone to tachycardia to meet the demands of the previously larger sized 
heart which is mediated by catecholamine release(30, 31). Tachycardia may worsen episodes of 
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myocardial ischaemia and significantly increases the production of oxygen free radicals by 
increased metabolic demand(32). These results in immune infiltration and activation, potentially 
causing acute or chronic rejection.  
Consequently, undersized hearts are shown to undergo pathological cardiac hypertrophy, which 
may cause fibrosis(33, 34). Fibrosis of myocardium and conduction fibres are likely to increase 
the risk of arrhythmias which may be misconstrued as rejection(35).  
 
Bypass time and blood transfusion 
Patients with PGD in our cohort had a significantly longer bypass time. We considered that this 
may have been due to the need to institute further treatment by means of insertion of IABP or 
institution of mechanical circulatory support. However, prolonged bypass time in itself is an 
independent predictor of morbidity and mortality in general cardiac surgery(36, 37).  
The mechanism of injury from CPB and ischaemic-reperfusion of the myocardium is similar; 
both producing a systemic inflammatory response syndrome (SIRS). They result in a 
hyperdynamic circulatory state due to the vasoplegia reducing vascular resistance, platelet and 
coagulation factor dysfunction, inflammatory pathway activation triggered by leucocytes and 
endothelial cells and finally cytokine release and formation of oxygen free radicals(38). 
Prolonged cardiopulmonary bypass also increases transfusion requirement(39). Our PGD cohort 
had higher blood transfusion requirements compared to the non-PGD cohort. This could once 
again be a response to the vasoplegic state caused by the SIRS effect from either prolonged 
bypass time or PGD itself. Blood transfusion in general cardiac surgery is associated with both 
infection and ischaemic postoperative morbidity, increased hospital stay, increased early and late 
mortality, and increased hospital costs(40, 41). In animal models, stored red blood cells have 
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implicated in causing organ hypoxia(42). Blood transfusion also increases pulmonary vascular 
resistance thereby affecting right ventricular ejection, without improving systemic or regional 
oxygen utilization(43). 
Given these findings, blood transfusion and cardiopulmonary bypass time may both contribute to 
the worsening of the ischaemic injury caused by PGD.  
 
Treatment of PGD 
Treatment of PGD is primarily supportive. As the definition of PGD is based on the treatment 
modality, mild and moderate PGD-LV is primarily inotropic support. Moderate PGD-LV is also 
treated with implantation of IABP. Escalation from this usually requires ECMO. Most cases of 
severe PGD-LV involve failure to wean from bypass, necessitating the institution of ECMO or 
short term VAD support. PGD-RV is initially treated with inotropic support including agents 
such as milrinone to promote pulmonary vasodilation. A RVAD is cited if right heart failure 
persists(3). Due to the shortage of organs and the increasing waiting list, re-transplantation is 
rarely done (3 in this study period). 
 
Limitations 
This was a retrospective analysis of prospectively collated national data. This study design is 
advantageous because the risk factors were recorded before the occurrence of the 
outcome(PGD). This is important because it allows the temporal sequence of risk factors and 
outcomes to be assessed. Selection bias was also minimized by including all adults with heart-
only transplants during the study period. However, as an observational study, only association 
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and not causation can be inferred from the results. Other unrecorded factors may have affected 
the outcome(44). 
As the data collected were from different hospitals, variations in practice was unaccounted for. 
This included postoperative immunosuppression regimes, choice of inotropes, myocardial 
preservation methods and MCS experience with some centers having a greater proportion of 
patients on LVADs. We relied on both PAC measurements and Echocardiography for defining 
PGD in patients without devices where possible. Some patients did not have PCWP readings and 
then we were reliant on echocardiographic criteria and vice versa. 
The ISHLT consensus definition relies on the use of mechanical circulatory support to define the 
more severe forms of PGD. The use of MCS was decided by individual surgeons and this is a 
potential weakness of the consensus definition. However, the national multicenter nature of this 
study is likely to have mitigated this problem. 
We performed an exploratory analysis of transplants performed on the OCS device but were 
unable to perform a multivariable analysis because of the limited number of cases and events.  
 
Conclusion 
PGD remains a significant risk factor for early mortality in heart transplant recipients. The 
standardized definition allows early diagnosis and recognition of this condition. There are 
several donor, recipient and procedural risk factors that may be contributory to the pathogenesis 
of PGD that should be considered for predicting outcomes. Further studies are warranted to 
establish the long-term outcomes of PGD using the current definition. 
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Recipient Factors PGD (n=163) Non-PGD (n=287) P- value 
Male:Female ratio 127:36 221:66 0.824 
Age (years) 47.1±14.1 46.1±13.8 0.449 
BMI (Kg/m
2
) 25.68±3.96 25.34±3.98      0.388 
Recipient Creatinine (μmol/L) 98.00 (48) 99.00 (46) 
 
0.217 
Recipient Diabetes Mellitus 19 (11.7%) 17 (5.9%) 0.031 
Recipient Re-sternotomy 33 (20.2%) 47 (16.4%) 0.302 
Preoperative Inotropes 82 (50.3%) 171(59.6%) 0.056 
Preoperative ECMO 5 (3.1%) 1 (0.3%) 0.023 
Preoperative IABP 15 (9.2%) 17 (5.9%) 0.193 
Preoperative LVAD 25(15.4%) 35(12.2%) 0.345 
Preoperative BiVAD 20(12.3%) 9(3.1%) <0.001 
Preoperative RVAD 3(1.8%) 20(7.0%) 0.018 
Preoperative antiarrythmics 58 (35.6%) 111(38.7%) 0.514 
Recipient Aetiology    
Ischaemic Cardiomyopathy 38 (23.3%) 62 (21.6%)  
 
 
 
 
 
 
0.464 
Dilated Cardiomyopathy 87 (53.3%) 160 (55.7%) 
Congenital Heart Disease 13 (8.0%) 26 (9.1%) 
HOCM 9 (5.5%) 15 (5.2%) 
Restrictive Cardiomyopathy 5 (3.1%) 8 (2.8%) 
Other 11 (6.7%) 7 (2.7%) 
Table 1. Preoperative characteristics of recipients 
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Donor Factors PGD (n=163) Non-PGD (n=287) p- value 
Donor Cause of death    
Intracerebral 
haemorrhage/Thrombosis 
107 (65.6%) 157 (54.7%) 0.023 
Hypoxic brain injury 21(12.9%) 48 (16.7%) 0.277 
Road Traffic 
Accident(RTA) 
23 (14.1%) 51(17.8%) 0.314 
Meningitis 4 (2.5%) 11 (3.8%) 0.434 
Brain Tumour 3 (1.8%) 8 (2.8%) 0.216 
Other 5 (3.1%) 10 (3.5%) (0.967 
Gender Mismatch 52 (31.9%) 59 (20.6%) 0.007 
Height Mismatch (%) -0.55 (6.8) -1.16 (6.8) 0.166 
Weight mismatch (%) -0.44 (27.8) -3.90 (33.8) 0.464 
Estimated LV mass 
mismatch (%) 
2.76 (25.5) -1.90 (25.3) 0.020 
Donor Age  41.6±12.2 38.5±12.4      0.010 
Donor LVEF (%) 57.77±9.36      
 
58.88±7.41    0.279 
Donor Smoker 74 140 0.489 
Table 2. Preoperative characteristics of donors 
Mismatch calculated as [(Measure (recipient) − Measure(donor)/Measure(recipient)] X 100 
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Operative Details PGD (n=163) Non-PGD (n=287) P- value 
Perfusion Solution  
St Thomas 139 (85.3%) 233 (81.2%)  
0.378 Custodiol 24 (14.7%) 51 (17.8%) 
*Cold Ischaemic Time 
(mins) 
103(66) 99(62) 
 
0.392 
Explant Time (mins) 17 (9) 
 
18 (10) 0.513 
Implant Time (mins) 56(24)  52(24) 0.017 
Warm Ischaemic Time 
(mins) 
72 (28) 70 (27) 0.045 
Total Ischaemic Time 
(mins) 
179 (86) 171(71) 0.426 
Bypass Time (mins) 206(113) 
 
162 (68) 
 
<0.001 
Postoperative details    
Right Atrial Pressure 
(mmHg)
 
 
13.01±4.37      
 
11.98±3.97      0.016 
PA Mean(mmHg)
 
 22.39±6.02      22.43±5.95      0.958 
PA Systolic(mmHg)
 
 31.75±9.52      32.08±9.23      0.789 
PCWP(mmHg)
 
 12.83±4.92     
  
13.53±5.76 0.355 
Transpulmonary 
Gradient (mmHg) 
8.000 (9) 
  
 
9.000 (8) 0.593 
Cardiac Index

  2.5654 (2.4) 
 
3.1074 (1.59) 0.005 
MAP (mmHg)
 
 73.1±15.2       
 
80.9± 16.9 <0.001 
Inotrope Score

 14.533(14.56) 
 
9.985(10.43) <0.001 
Blood Products 
Transfused (units) 
9 (11) 5 (6)  <0.001 
RBCs(units) 4(7) 2(3) <0.001 
FFP(units 2.000 (2.8) 
 
2.000 (4) 0.032 
Platelets(units) 2.0000 (2) 
 
1.0000 (2) <0.001 
Table 3: Postoperative details  
*Excluding patients on OCS 

Part of ISHLT 2014 severity definition 
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Factors Odds Ratio 95% Confidence 
Intervals 
P- value 
Donor age 
 
1.02 (1.0043, 1.0383) 
 
0.014   
Implant time 
 
1.01  (1.0005, 1.0195) 0.038   
Female: male 
mismatch 
 
1.74 
 
(1.0464, 2.9086) 0.033   
Recipient diabetes 
 
2.04  (0.9993, 4.1720) 0.051 
Preoperative 
VAD/ECMO support 
1.79  (1.1371, 2.8295) 0.012 
Table 4: Results of multivariable analysis for risk factors for PGD 
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Factors Odds Ratio 95% Confidence 
Intervals 
P- value 
Implant time 1.02 (1.0003, 1.0342) 0.037 
Female: male mismatch 2.43 (1.0966, 5.3722) 0.026 
Recipient Resternotomy 
 
3.21  (1.3215, 7.8084 0.008 
Table 5: Results of multivariable analysis for risk factors for severe PGD 
